Medical devices, healthcare technology and the business of care
PMA approval · P160030

Freestyle Libre Flash Glucose Monitoring System

Abbott Diabetes Care, Inc. · Decision date Sep 27, 2017

FDA DECISIONP160030

What did the FDA approve?

FDA records P160030 as an original PMA application. The recorded decision is approval, dated Sep 27, 2017.

FDA approval order statement

Approval for the Freestyle Libre Flash Glucose Monitoring System. The FreeStyle Libre Flash Glucose Monitoring System is a continuous glucose monitoring (CGM) device indicated for the management of diabetes in persons age 18 and older. It is designed to replace blood glucose testing for diabetes treatment decisions.The System detects trends and tracks patterns aiding in the detection of episodes of hyperglycemia and hypoglycemia, facilitating both acute and long-term therapy adjustments. Interpretation of the System readings should be based on the glucose trends and several sequential readings over time. The System is intended for single patient use and requires a prescription.
Regulatory pathway
Original PMA
Clinical specialty
Clinical Chemistry
Decision date
Sep 27, 2017

FDA source record

Regulatory record facts

Identifier
P160030
Regulatory pathway
Premarket approval application
Product code
PZE
Decision code
APPR
Decision date
Sep 27, 2017
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Sensor, glucose, invasive, non-adjunctive, factory-calibrated, user-initiated.

Product code
PZE
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P160030 received

    Application receipt date recorded by FDA.

  2. P160030 · FDA decision

    APPR

  3. P160030/S058 · Related supplement

    Freestyle Libre Flash Glucose Monitoring System

Timeline entries are records held by MedtechLedger for P160030. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P160030

Product / regulatory recordCompanyPathwayDecision dateSource
Abbott Diabetes Care, Inc.PMA supplementSep 1, 2026FDA

Explore the linked device profile

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Abbott Diabetes Care, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1360 S. Loop Dr., Alameda, CA, 94502

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records